Off the Radar: How Unapproved AI Is Complicating Healthcare Cyber Risk
You cannot secure what you cannot see, and right now, healthcare organizations are accumulating hidden cyber liabilities with every keystroke.
Protecting Your Biotech: Understanding the Risks of Compounded GLP-1s
With the global market for anti-obesity drugs projected to hit $95 billion by 2030, it’s no surprise that compounded semaglutide is gaining traction as a cheaper, more accessible option. But for all its appeal, this route comes with real risks: regulatory uncertainty, legal exposure, and major insurance hurdles.
presented by
Closing the Quality-Affordability Gap in Workplace Mental Health
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.